Search research articles
Contact Us
Filters
Showing results (11-20 of 34) with videos related to
Page
of 4
Sort By:
Nutrition (Burbank, Los Angeles County, Calif.)
|
August 3, 2020
Creatinine-to-cystatin C ratio and bioelectrical impedance analysis for the assessement of low lean body mass in cancer patients: Comparison to L3-computed tomography scan
Guillame Ulmann, Joanna Kaï, Jean-Philippe Durand, et al.
The American Journal of Clinical Nutrition
|
March 31, 2017
Relation between hypermetabolism, cachexia, and survival in cancer patients: a prospective study in 390 cancer patients before initiation of anticancer therapy
Clara Vazeille, Anne Jouinot, Jean-Philippe Durand, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
May 31, 2012
Interaction between serotonin reuptake inhibitors, 5-HT3 antagonists, and NK1 antagonists in cancer patients receiving highly emetogenic chemotherapy: a case-control study
Olivier Mir, Jean-Philippe Durand, Pascaline Boudou-Rouquette, et al.
Journal of Oncology Practice
|
November 28, 2012
Cost effectiveness of integrated medicine in patients with cancer receiving anticancer chemotherapy
Romain Coriat, Pascaline Boudou-Rouquette, Jean-Philippe Durand, et al.
Investigational New Drugs
|
May 27, 2011
Safety of bevacizumab 7.5 mg/kg infusion over 10 minutes in NSCLC patients
Olivier Mir, Jérôme Alexandre, Romain Coriat, et al.
The Oncologist
|
August 3, 2011
An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity
Olivier Mir, Romain Coriat, Laure Cabanes, et al.
Anti-Cancer Drugs
|
June 16, 2012
Feasibility of gemcitabine and oxaliplatin in patients with advanced biliary tract carcinoma and a performance status of 2
Olivier Mir, Romain Coriat, Marion Dhooge, et al.
Annals of Nutrition & Metabolism
|
December 23, 2019
Lean Body Mass and Endocrine Status But Not Age Are Determinants of Resting Energy Expenditure in Patients with Non-Small Cell Lung Cancer
Guillaume Ulmann, Anne Jouinot, Camille Tlemsani, et al.
Medical Oncology (Northwood, London, England)
|
March 20, 2012
Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib
Olivier Mir, Romain Coriat, Pascaline Boudou-Rouquette, et al.
Plos One
|
June 6, 2012
Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma
Olivier Mir, Romain Coriat, Benoit Blanchet, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 34) with videos related to
Sort By:
Page
of 4
Nutrition (Burbank, Los Angeles County, Calif.)
|
August 3, 2020
Creatinine-to-cystatin C ratio and bioelectrical impedance analysis for the assessement of low lean body mass in cancer patients: Comparison to L3-computed tomography scan
Guillame Ulmann, Joanna Kaï, Jean-Philippe Durand, et al.
The American Journal of Clinical Nutrition
|
March 31, 2017
Relation between hypermetabolism, cachexia, and survival in cancer patients: a prospective study in 390 cancer patients before initiation of anticancer therapy
Clara Vazeille, Anne Jouinot, Jean-Philippe Durand, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
May 31, 2012
Interaction between serotonin reuptake inhibitors, 5-HT3 antagonists, and NK1 antagonists in cancer patients receiving highly emetogenic chemotherapy: a case-control study
Olivier Mir, Jean-Philippe Durand, Pascaline Boudou-Rouquette, et al.
Journal of Oncology Practice
|
November 28, 2012
Cost effectiveness of integrated medicine in patients with cancer receiving anticancer chemotherapy
Romain Coriat, Pascaline Boudou-Rouquette, Jean-Philippe Durand, et al.
Investigational New Drugs
|
May 27, 2011
Safety of bevacizumab 7.5 mg/kg infusion over 10 minutes in NSCLC patients
Olivier Mir, Jérôme Alexandre, Romain Coriat, et al.
The Oncologist
|
August 3, 2011
An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity
Olivier Mir, Romain Coriat, Laure Cabanes, et al.
Anti-Cancer Drugs
|
June 16, 2012
Feasibility of gemcitabine and oxaliplatin in patients with advanced biliary tract carcinoma and a performance status of 2
Olivier Mir, Romain Coriat, Marion Dhooge, et al.
Annals of Nutrition & Metabolism
|
December 23, 2019
Lean Body Mass and Endocrine Status But Not Age Are Determinants of Resting Energy Expenditure in Patients with Non-Small Cell Lung Cancer
Guillaume Ulmann, Anne Jouinot, Camille Tlemsani, et al.
Medical Oncology (Northwood, London, England)
|
March 20, 2012
Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib
Olivier Mir, Romain Coriat, Pascaline Boudou-Rouquette, et al.
Plos One
|
June 6, 2012
Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma
Olivier Mir, Romain Coriat, Benoit Blanchet, et al.
Page
of 4